Important Change for Entries in EudraGMDP Database
![European GMPs and the Role of the Qualified Person (QP) (Day 1 and 2) + Clinical Trial Supplies (Day 3) – Live Online Training](files/eca/userImages/training.img/Z-ECA-European-GMPs-and-Role-of-QP-2025.jpg)
Recommendation
10-12 February 2025
The Impact of EU Legislation on the Supply Chain
The new regulatory framework for veterinary medicinal products requires several changes to the EudraGMDP database. One important change is the integration of EudraGMDP into the EMA's Organisation Management Service (OMS).
From 28 January 2022, users of EudraGMDP from national competent authorities will no longer introduce organisational data (organisation name and location address details) directly into the relevant fields on the EudraGMDP database. Instead, they will select the relevant organisation name and location address details, including the legally registered address, of the manufacturers/importers/distributors from the Agency's organisation dictionary (so-called OMS).
It is therefore necessary that all organisations currently regulated through EudraGMDP (which appear on documents within EudraGMDP, including EU and non-EU manufacturers, importers and distributors of human and veterinary medicinal products and active substances) are registered in OMS.
For this purpose, EMA is organising a webinar (Integration of EudraGMDP and OMS - Webinar for industry).
The webinar for industry users will cover:
- Integration of EudraGMDP and OMS - implications for industry users;
- OMS services and activities;
- OMS change request process;
- customer service (EMA Service Desk)
- data quality management.
Related GMP News
05.02.2025Inadequate Analytical and Microbiological Controls - FDA Warning Letter to Indian Company
29.01.2025FDA Warning Letter to Chinese Manufacturer of OTC Products
29.01.2025Warning Letter - No Testing for EC/DEG and other Deficiencies
08.01.2025PIC/S publishes Guidance Documents on Remote Assessments
04.12.2024Discarded Batch Documentation again found during Inspection
30.10.2024From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer